disease

Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease

AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient Study has been seen by millions following its…

9 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease

October 22, 2025 16:30 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

9 months ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12…

9 months ago

Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9,…

9 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…

9 months ago

HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease

HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology…

9 months ago

LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China

September 28, 2025 19:30 ET  | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai…

10 months ago

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2Elevated lipoprotein(a) or Lp(a), an inherited condition…

10 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

10 months ago

Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease

MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative…

10 months ago